On the other hand, in IMpower 133, the trial that led to the approval of atezolizumab in addition to chemotherapy in the first line treatment of ES-SCLC, the benefit was noted across all patient subgroups regardless of PD-L1 status [43]. This evidence concerns the gene CD274 and small cell lung carcinoma.